1 Premorbid predictors of a fatal initial presentation of coronary heart disease among post-

- 2 menopausal women
 - SHORT TITLE: Predictors of fatal incident CHD in the WHI
- 4 Ming-Li Chen, MD, MS^{a,b}, Jin Li, PhD^{a,c}, Kruthika R. Iyer, PhD^{a,b,d}, Catherine Tcheandjieu,
- 5 PhD^{a,b,d}, Shirin Jimenez, MD^{a,e}, Elias Levy Itshak Salfati, PhD^{a,f}, Liana C. Del Gobbo, PhD^a,
- 6 Marcia L Stefanick, PhD^a, Manisha Desai^a, PhD, Xiaonan Xue, PhD^b, Themistocles L Assimes,
- 7 $MD PhD^{a,b}$

- ^aDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA
- 9 ^bPalo Alto VA Healthcare System, Palo Alto, CA, USA
- 10 ^cThermo Fisher Scientific, South San Francisco, CA, USA
- ¹¹ ^dGladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco,
- 12 CA, USA
- ¹³ ^eDepartment of Internal Medicine (Division of Cardiovascular Medicine), University of
- 14 California Davis Health, Davis, CA, USA
- ¹⁵ ¹⁵ Scripps Research Translational Institute at Scripps Research, La Jolla, CA, USA
- ^gDivision of Biostatistics, Department of Epidemiology & Population Health, Albert Einstein
- 17 College of Medicine, Bronx, New York, USA
- 18 Address for correspondence:
- 19 Themistocles L. Assimes, MD PhD
- 20 Palo Alto VA Hospital, 3801 Miranda Ave., Palo Alto, CA 94304
- 21 email: <u>tassimes@stanford.edu</u>
- 22 Total word count of the manuscript (including Title Page, Abstract, Text, References, Tables and
- 23 Figures Legends): 6317 (Text 3581)

24 Abstract

Background: Premorbid health traits that predispose to a fatal initial presentation of coronary
 heart disease (CHD) remain poorly characterized.

27 Methods: We followed 148,230 post-menopausal participants in the Women's Health Initiative

- for a median of 13.3 years. We ascertained the first occurrence of CHD and performed a joint
- 29 Cox multivariate regression to identify premorbid predictors for a fatal rather than a non-fatal
- 30 incident event.

31 **Results**: A total of 10,714 incident CHD events including 513 fatal events accrued during follow

32 up. A five-year increase in age, smoking 5 to 34 cigarettes per day, and a standard deviation (SD)

33 increase in the Cornel voltage product on electrocardiography each independently increased the

relative risk (RR) of dying from one's initial presentation of CHD by 46% (95% confidence

35 interval [CI], 35 to 58%), 30% (8 to 51%,), and 17% (7 to 28%), respectively. A high level of

36 recreational physical activity (>1200 metabolic equivalent (MET) minutes per week) reduced

37 one's relative risk by 32% (12 to 49%). A significant dose-response effect was observed for both

38 physical activity and smoking and the reduction in absolute risk of presenting with fatal CHD

39 associated with a healthy lifestyle was roughly equivalent to the difference in risk observed

40 among women separated in age by approximately 10 years.

41 **Conclusions**: Modifiable factors affect a post-menopausal woman's risk of dying from her initial

42 presentation of CHD. Our findings may reduce case-fatality rates of CHD by motivating

43 individuals at risk to adopt and/or adhere to established primary prevention strategies.

45 Key Words

- 46 Coronary Heart Disease; Fatal Initial Presentation; Post-menopausal Women; Women's Health
- 47 Initiative; Left Ventricular Mass; Electrocardiography; Modifiable Risk Factor; Smoking;
- 48 Physical activity; Aspirin.

49 Clinical Perspective

- What Is New? Older age, smoking, and increased left ventricular mass as estimated by
- 51 electrocardiography independently increase the risk of a fatal outcome with the initial
- 52 presentation of CHD, while physical activity and the use of aspirin reduced that risk.
- What Are the Clinical Implications? Modifiable risk factors related to lifestyle not only
- 54 protect against the occurrence of an initial presentation of CHD but also provide
- 55 additional protection against a fatal outcome during that event.

57 Introduction

Initial presentations of coronary heart disease (CHD) include stable angina, acute coronary 58 syndrome (ACS), and myocardial infarction (MI). A minority of subjects suffer a fatal 59 60 consequence from their initial presentation, but this outcome is arguably one of the most devastating events encountered by patients, their family members, and healthcare providers.¹ 61 62 Individuals dying from their initial presentation of CHD miss the opportunity to benefit from well-established secondary prevention strategies that reduce the risk of recurrent events.² 63 64 Multiple studies have demonstrated a sustained decline in the overall rates of CHD over the last few decades in developed countries.³ This decline comes on the heels of the 65 implementation of several primary and secondary prevention strategies.^{2,4} However, the decline 66 in the rates of fatal CHD has not been as steep as CHD overall.^{1,5} Some studies have shown that 67 68 the rate of fatal CHD has remained stable over time among subjects with no prior history of CHD and may have even increased among elderly individuals.⁵ Furthermore, lifetime risks of 69 CHD and sudden cardiac death in the community remain high.^{6,7} These trends underscore the 70 71 need to identify premorbid predictors of a fatal outcome related to incident CHD. 72 The premorbid predictors for a fatal outcome with the initial presentation of CHD remain

poorly characterized. In the Cardiovascular Health Study (CHS), the only independent predictors
of fatal CHD outcomes among subjects with no prior history of CHD, MI, or CHF at baseline
were diabetes and age⁸. The study was limited by the small number of events, the narrow range
of age of elderly participants, and the lack of assessment of lifestyle factors. In this study, we
leveraged the large size and the prolonged follow-up of the Women's Health Initiative (WHI) in

78 combination with the repeated assessment of exposures and the careful adjudication of CHD

79 outcomes to document independent predictors of a fatal presentation of CHD more reliably.

80 Methods

81 Study cohort

82 A detailed description of study design, recruitment, and initial characterization for WHI has been previously published.⁹⁻¹¹ The study cohort consisted of 148,230 participants enrolled in either 83 84 one of the clinical trials (n=63170) or the observational study (n=85060) between 1993 and 1998 85 with no history of atherosclerotic cardiovascular disease or congestive heart failure at baseline 86 (Figure 1). All participants were followed through 2010 and a subset of participants (n=88550) 87 with continued adjudication of CHD outcomes were further followed until 2015. The WHI 88 project was reviewed and approved by the Fred Hutchinson Cancer Research Center (Fred 89 Hutch) Institutional Review Board (IRB). Participants provided written informed consent to 90 participate. Additional consent to review medical records was obtained through signed written 91 consent.

92 Outcome ascertainment

The primary endpoints for this study were newly diagnosed CHD events including angina, nonfatal myocardial infarction (MI), coronary revascularization through either a percutaneous
coronary intervention or coronary artery bypass grafting, and definitive death from CHD.
Adjudication methods for cardiovascular disease outcomes in the WHI have been previously
described extensively¹². The diagnosis of nonfatal MI was confirmed if data in the hospital
record met standardized criteria of diagnostic electrocardiographic changes, elevated cardiac
enzyme levels, or both. Treatment with coronary revascularization was confirmed by

100 documentation of the procedure in the medical record. Fatal CHD was considered confirmed if 101 there was documentation in the hospital or autopsy records or if coronary disease was listed as 102 the cause of death on the death certificate and evidence of previous coronary disease was 103 available. Adjudication of these events occurred for all participants through the clinical trial and 104 intervention phase (1993-2005) as well as the first extension (2005-2010). Adjudication of CHD 105 events during the second extension study (2010-2015) was restricted to a subset of participants in 106 the Medical Record Cohort (MRC). We considered all adjudicated events occurring within 28 107 days of the initial event in classifying whether the initial presentation was fatal or not fatal. Thus, 108 women who had a fatal event within 28 days of their initial non-fatal event were classified as 109 fatal events.

110 Exposure Assessment

111 Information on exposures was collected at baseline through an in-person clinic visit and through 112 multiple self-administered questionnaires that collected information on demographic factors 113 including age, race/ethnicity, education, income, medical history, physical activity (PA) levels, 114 smoking habits, and diet. Women who participated in any clinical trial also underwent a 12-lead 115 electrocardiogram (ECG). Additional self-administered questionnaires were collected regularly 116 during follow up allowing for repeated measures of medical history, medication use, PA levels, 117 and smoking habits. The data collection schedule during follow-up varied by cohort (clinical 118 trials vs. observational study) and by the study phase (intervention vs. observational phase). 119 Complete details on the collection schedule and the derivation of variables are provided in **Table** 120 **S1**.

121 We used the medication inventory to document the use of aspirin, statins, beta-blockers, 122 calcium channel blockers (CCBs), inhibitors of the renin-angiotensin system (RAS), and 123 diuretics. Participant's level of PA was categorized into four groups based on weekly energy expenditure in metabolic equivalents (MET) minutes.¹³ In addition to typical ECG intervals, we 124 125 tested several derived ECG variables related to left ventricular mass/hypertrophy and ECG 126 abnormalities indicating possible subclinical MI/Ischemia or bradycardia. Through six ancillary 127 studies, a subset of all WHI participants underwent genome-wide genotyping followed by joint 128 imputation to the 1000G reference panel (dbGaP study accession: phs000746.v1.p3) We used 129 this data to construct a previously validated genetic risk score for CHD (metaGRS) consisting of 130 genetic variants summarizing a participant's exposure to high-risk variants at 1.7 million polymorphic sites¹⁴. We restricted the metaGRS analysis to non-Hispanic white participants 131 132 given the score was constructed using almost exclusively a non-Hispanic white population and has been shown to perform best in the same population¹⁴. Through separate ancillary studies, 133 134 seven blood-based biomarkers related to cardiovascular disease were measured using 135 standardized assays in a subset of WHI participants including high density lipoprotein 136 concentration (HDL), low density lipoprotein concentration (LDL), triglycerides, creatinine, 137 insulin, glucose, and high sensitivity C-reactive protein (hsCRP). Complete details of exposure 138 assessment are in **Supplemental Material**.

139 Statistical Analyses

We used a joint multivariate Cox model to estimate the hazard ratio of a predictor of
interest with each of the two subtypes of presentation of incident CHD, fatal and non-fatal,
simultaneously.¹⁵⁻¹⁸ More extensive details on the statistical modeling implemented is provided

143 in the Supplemental Material. Predictors of interest were included in a multivariate model if 144 they demonstrated a significant association with CHD in a minimally adjusted model that 145 included age and race. Among the predictors of interest, we modeled body mass index (BMI), 146 systolic blood pressure (SBP), smoking status, amount of weekly recreational physical activity, 147 treated hypertension, treated diabetes, and class of medication use as time-dependent covariates 148 while the other risk factors measured at baseline were modeled as time-fixed covariates. For 149 main analyses, missingness of covariates were imputed with multiple imputation method, using 150 linear mixed effect where covariates were modeled mostly as random effect, resulting in a predicted value close to the predicted value of the missing sample^{19,20}. We corrected for multiple 151 152 testing of predictors included in the multivariate model using the Benjamini-Hochberg method and a false discovery rate (FDR) of 0.05^{21} . Lastly, we further performed subgroup analyses 153 154 limited to the subsets of participants with ECG measures, blood biomarkers, and genetic data. 155 These variables were tested by adding them last to the main model containing the covariates 156 included in the main analyses. 157 Next, we used the same joint multivariate Cox model to estimate the probability of i.

157 Next, we used the same joint multivariate Cox model to estimate the probability of 1. 158 developing incident non-fatal CHD over a follow up period of 20 years and ii. the probability of 159 a fatal incident CHD event taking into consideration the competing risk of a non-fatal CHD 160 event. We calculated and compared these hazard functions for women at different ages and with 161 various combination of exposures of interest based on the results of our multivariate analysis. 162 All analyses were performed using R.

163 **Results**

164	A total of 10201 non-fatal and 513 fatal incident CHD events accrued among 148,230
165	participants during a median follow-up time of 13.3 years for an overall incident CHD rate of
166	7.2% and a case-fatality rate of 5.0% (Figure 1, Table 1). Compared to women with no events,
167	women with an incident CHD event during follow up were older, had a lower socioeconomic
168	status, more often were current smokers, and had a lower degree of recreational physical activity
169	(PA) at baseline (Table 1). Women with CHD events also had a higher BMI and blood pressure,
170	as well as a higher prevalence of treated hypertension and treated diabetes. Lastly, women with
171	CHD events also had a higher use of aspirin, statins, beta-blockers, calcium channel blockers,
172	renin-angiotensin inhibitors, and thiazide-like diuretics (Table 1).
173	Our statistically most significant predictor of a fatal outcome at the time of an incident
174	CHD event was age (Table 2). For each five-year increase in age, women were at a substantially
175	increased risk for both fatal and non-fatal initial presentations of CHD. However, the increase in
176	the risk for a fatal presentation was 46% greater (95% Confidence interval [CI] 35% to 58%)
177	than that observed for a non-fatal presentation (Table 2).
178	Our second statistically most significant predictor of a fatal outcome at the time of
179	incident CHD was aspirin use (Table 2). Women who took aspirin and developed a CHD event
180	in WHI had a 31% (95% CI: 16 to 44%) lower risk of dying from their initial presentation of
181	CHD than women who did not take aspirin (Table 2). Women taking aspirin, statins, beta-
182	blockers, and CCBs had a highly significant increased risk of non-fatal CHD ranging from 19 to
183	32% (Table 2). Similar hazard ratios for fatal CHD were observed with the use of beta-blockers
184	and CCBs.

185	Our third statistically most significant predictor was smoking (Table 2, Figure 2A,2C).
186	The relative hazard ratio of fatal vs. non-fatal CHD outcomes was similar for women reporting
187	5-14, 15-24, and 25-34 cigarettes per day. Thus, these exposure groups were combined. Women
188	who smoked within a range of 5 to 34 cigarettes/day (weighted average of ~16 cigs/day) suffered
189	from an increase in the risk of both fatal and non-fatal initial presentations of CHD when
190	compared to women who were non-smokers. However, the increase in risk for a fatal
191	presentation was 28% greater (95% CI: 5% to 56%) than that observed for a non-fatal
192	presentation (Figure 2C). Women with higher levels of smoking also observed a greater increase
193	in the risk of fatal events compared to non-fatal events, with a ~14% greater increase (95% CI: 4
194	to 23%) of risk observed per increasing level of smoking (Table 2).
195	Our fourth statistically most significant predictor was recreational physical activity (PA)
196	(Table 2, Figure 2B, 2D). Women reporting a high amount of PA benefited from a reduction in
197	the risk of both fatal and non-fatal initial presentations of CHD when compared to sedentary
198	women. However, the reduction in risk for a fatal presentation was 36% greater than that
199	observed for a non-fatal presentation (Figure 2D). Women with intermediate levels of PA also
200	observed a greater reduction in the risk of fatal events compared to non-fatal events, with a 16%
201	greater reduction of risk observed per increasing level of PA (Table 2).
202	Next, we analyzed subgroups of women with ECG measures, blood biomarkers, and
203	genetic data. Summary statistics of all the ECG measurements at baseline are provided in Table
204	S3. Due to high correlation, we excluded a subset of ECG measurements from our analyses
205	(Table S4). Two predictors were significant at an FDR<0.05. Both were measures related to the
206	baseline ECG. The most significant predictor was the Cornell voltage product, a measure that
207	correlates with left ventricular mass on echocardiography (Table S5) ²² . The increase in risk for a
	(1)

fatal presentation was 17% (95% CI: 7 to 28%) greater than that observed for a non-fatal
presentation per one SD increase in the Cornell Voltage product. Similar magnitude of increased
risk was observed for the QRS duration (17%, 95% CI: 6 to 29%) (Table S5). We found no
difference in the risk of dying from the initial presentation of CHD associated with a widely
validated polygenic risk score (meta-GRS), LDL, HDL, triglycerides, creatinine, hs-CRP, and
heart rate.

214 We estimated the cumulative probability of presenting with an incident CHD event that 215 was fatal over 20 years of follow up for women aged 55, 65, and 75 years at baseline to be 0.1%, 216 0.37%, and 1.2%, respectively, for women with a healthy lifestyle (no smoking and > 1200 MET 217 min/week of PA) and 0.4%, 1.3%, and 4.1% for women with an unhealthy lifestyle (smoking 35 218 to 44 cigarettes/day and < 100 MET min/week of PA) (Figure 3a, Table S6). The analogous 219 cumulative probabilities for presenting with a non-fatal incident CHD event were 3.7%, 5.8%, 220 and 9.1% for a healthy lifestyle and 6.0%, 9.4%, and 14.4% for an unhealthy lifestyle (Table 221 **S6**). Taking aspirin reduced the probability of fatal-CHD from 1.2% to 1.0% among 75-year 222 women with a healthy lifestyle and 4.1% to 3.3% among women with an unhealthy lifestyle 223 (Figure 3b, Table S6). However, the analogous cumulative probabilities for non-fatal CHD 224 increased from 9.1% to 10.7%, and from 14.4% to 17.0%, among women aged 75 years with a 225 healthy and an unhealthy lifestyle, respectively (**Table S6**). Overall, the ratio of fatal to total 226 (fatal and non-fatal) presentations of CHD decreased from 6.1% to 2.9% for 55-year-old women 227 with a healthy lifestyle compared to women with an unhealthy lifestyle (**Table S6**). Analogous 228 reductions in this ratio for women aged 65 and 75 at baseline were 12.0% to 6.0% and 22.3% to 229 11.9%, respectively (**Table S6**). The use of aspirin among 75-year-old women decreased this

ratio from 11.9% to 8.5% among 75-year-old women with a healthy lifestyle and from 22.3% to
16.4% for women with an unhealthy lifestyle (**Table S6**).

232 **Discussion**

We conducted to our knowledge the largest study to date of the premorbid predictors of the mode of presentation of CHD by leveraging data collected from the largest and longest-running cohort study of post-menopausal women in the United States. We summarize our findings thematically around four key observations.

237 First, we found older age, physical activity, smoking, aspirin use, and two ECG-derived 238 measures (Cornell Voltage as a proxy for LV hypertrophy/mass and QRS duration) to be 239 independent predictors of a fatal outcome among participants suffering their first-ever CHD 240 event. While the findings for age and LVH are consistent with previously published findings, the 241 remaining associations have not been previously reported in this specific context. The 242 association between a prolonged QRS and a fatal outcome is plausible given a common cause of such prolongations is coronary artery disease $^{23-26}$. Thus, these measures may be serving as 243 markers of advanced subclinical CHD^{23-26} . These prolongations may also be predisposing to fatal 244 arrhythmic events in the setting of ACSs²³⁻²⁶. Importantly, the non-ECG associations involve 245 246 highly modifiable risk factors which have the potential to profoundly affect the case-fatality rate 247 of incident CHD if they are optimally embraced at the population level.

Second, we could not replicate diabetes as an independent risk factor for an elevated short term (<28 days) case-fatality rate of CHD as was observed in the CHS study⁸ despite diabetes roughly doubling the risk of both incident and fatal CHD in WHI. To explain this discrepancy, we note that follow up and events for CHS accrued during the late 1980s and early

252 1990s while for WHI they accrued during the late 1990s, 2000s, and early 2010s. During this time, multiple other studies of cohorts in Finland, Germany, and Australia²⁷⁻²⁹ have shown 253 254 substantial reductions in the case-fatality rates among subjects with and without diabetes 255 including one study showing diabetes was no longer a predictor of increased case-fatality rate by 256 2010²⁹. Differences in other demographic and clinical characteristics between CHS and WHI including baseline age distribution, prevalence and severity of diabetes, and education status ²⁸ 257 258 may have also decreased power to detect this association. For example, the baseline prevalence of diabetes in CHS was 25.2%⁸ while it was only 3.6% in WHI. 259 260 Third, we found a healthy lifestyle at baseline (defined as no smoking and > 1200 MET

261 min/week of PA) when compared to an unhealthy lifestyle (smoking 35 to 44 cigarettes/day and 262 < 100 MET min/week of PA) to be associated with a reduction in the cumulative probability of 263 dying from one's initial presentation of CHD equivalent to the reduction observed among groups 264 of women separate by an approximately a decade in age. The effect of aspirin on lowering this 265 risk was not as pronounced but still significant for all post-menopausal women.

Lastly, we note that probability of dying from initial presentation of CHD had a more rapid rate of increase relative to the probability of presenting with a non-fatal CHD over time, leading to an increasing absolute difference in the probability of dying from the initial presentation of CHD over time. This increasing difference became particularly evident in the second decade of follow-up. Thus, a healthy lifestyle at baseline is associated with a larger protection from a fatal incident CHD event late in life.

272 Strengths of our study include the long duration of follow-up, the availability of a very 273 large number of carefully adjudicated incident fatal and non-fatal CHD events, and the repeated 274 assessment of multiple exposures. Our baseline cohort produced over seven times the number of

incident fatal CHD outcomes compared to the CHS study⁸. Our time-dependent analyses using a
joint Cox model allowed us to optimally model the short-term effects of multiple exposures such
as physical activity, smoking, and medications.

278 The limitations of this study should be considered carefully. First, our analysis of the 279 most used classes of cardiovascular drugs was disadvantaged by the presence of confounding by 280 indication given prior clinical trials have unequivocally established the protective effects of aspirin and statins on the risk of incident CHD³⁰. This type of confounding is common in 281 282 observational studies reporting on the intended effects of pharmacological therapies and often cannot be corrected through covariate adjustment³¹. However, this confounding may be 283 284 minimized or even eliminated when estimating the difference in risk reduction between fatal and 285 non-fatal CHD events if it is in the same direction, and present to an equal degree, for both types 286 of outcomes. Furthermore, the protective effect observed against fatal outcomes is biologically 287 plausible given aspirin's established role in limiting the extent of occlusive thrombosis that 288 follows a plaque rupture. Second, we examined only post-menopausal women. We suspect that 289 our findings do generalize to other populations although further study in large cohorts is needed 290 to definitively prove this hypothesis. Third, we had reduced power to detect differences in the 291 hazard ratios between fatal and non-fatal presentations of disease for our assessment of 292 biomarkers and genetic risk. These risk factors need to be further examined in other large cohorts 293 before definitive conclusions can be made. Fourth, no systematic assessment of LV function was available in WHI making it impossible to compare our results to the CHS in this respect⁸. 294 295 However, routine assessment of LV function in asymptomatic individuals is not recommended 296 for risk stratification. Lastly, we could not adjust for in hospital treatments that may have 297 influenced case-fatality rates of CHD such as time from symptom onset of ACS to hospital

presentation for thrombolytic therapy or primary coronary intervention, as such information was not collected by WHI¹². Older age, diabetes, and smoking have been linked to prehospital delays involving ACSs and may be contributing to our observed results³². We note that smoking has been associated with a shorter prehospital delay perhaps due to the widely publicized link between smoking and the risk of CHD ³². Thus, the increased risk of fatal presentation we observed for smoking may be an underestimate of the true effect.

304 Our analysis yields three insights within the framework of existing evidence and 305 prevention protocols. First, the American Heart Association recommends either 150 minutes of 306 moderate-intensity aerobic PA per week or 75 minutes of vigorous PA per week for the 307 maintenance of optimal cardiovascular health. These levels of PA translate to ~750 MET 308 minutes per week. However, more extensive health benefits have been observed with additional PA³³. Our findings suggest that higher levels of aerobic PA will have a more profound beneficial 309 310 effect on a woman's chances of dying from an incident CHD event. Second, we note that despite 311 an established monotonic increase in the risk of CHD between individuals who smoke five and individuals who smoke 30 cigarettes per day³⁴, the benefit we observed with respect to fatal 312 313 outcomes over non-fatal outcomes in this range was relatively flat. Thus, our findings suggest 314 that even smoking lightly disproportionally increases a woman's risk of dying from her initial 315 CHD event. Third, the use of aspirin in the primary prevention of CHD has been controversial 316 with the most recent statement recommending the potential use for individuals aged 40-59 years of age with a >10% 10-year risk of atherosclerotic cardiovascular disease³⁵. However, these 317 318 recommendations consider the elevated risk of bleeding associated with aspirin use³⁵. We did not 319 examine bleeding side effects in this study but still provide evidence that the risk of dying from 320 one's initial presentation of CHD is reduced with the use of aspirin.

321 Conclusions

322	In conclusion, our study found that older age, smoking, and two ECG-related measures including
323	LVH and prolonged QRS increased the risk of dying from a first ever presentation of CHD,
324	while physical activity and aspirin reduced this risk. This information may be used as an
325	effective motivator for women to optimize their lifestyle and significantly reduce their overall
326	risk of CHD but also their chances of dying from their initial event. These benefits are likely to
327	extend to other populations including pre-menopausal women and men, but further study is
328	needed to prove this hypothesis more definitively.
329	Acknowledgements
330	We acknowledge the contributions of the following past and present key WHI investigators:
331	Program Office: (National Heart, Lung, and Blood Institute, Bethesda, Maryland) Jacques
332	Rossouw, Shari Ludlam, Joan McGowan, Leslie Ford, and Nancy Geller
333	Clinical Coordinating Center: (Fred Hutchinson Cancer Research Center, Seattle, WA) Garnet
334	Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg
335	Investigators and Academic Centers: (Brigham and Women's Hospital, Harvard Medical
336	School, Boston, MA) JoAnn E. Manson; (MedStar Health Research Institute/Howard University,
337	Washington, DC) Barbara V. Howard; (Stanford Prevention Research Center, Stanford, CA)
338	Marcia L. Stefanick; (The Ohio State University, Columbus, OH) Rebecca Jackson; (University
339	of Arizona, Tucson/Phoenix, AZ) Cynthia A. Thomson; (University at Buffalo, Buffalo, NY)
340	Jean Wactawski-Wende; (University of Florida, Gainesville/Jacksonville, FL) Marian Limacher;
341	(University of Iowa, Iowa City/Davenport, IA) Jennifer Robinson; (University of Pittsburgh,

- 342 Pittsburgh, PA) Lewis Kuller; (Wake Forest University School of Medicine, Winston-Salem,
- 343 NC) Sally Shumaker; (University of Nevada, Reno, NV) Robert Brunner
- 344 Women's Health Initiative Memory Study: (Wake Forest University School of Medicine,
- 345 Winston-Salem, NC) Mark Espeland

Sources of Funding

- 347 The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes
- of Health, U.S. Department of Health and Human Services through contracts 75N92021D00001,
- 349 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005.

350 Role of the funding source

- 351 The funding agency had no role in study design, data collection, analysis, or writing of this
- 352 report. The corresponding author had full access to the study data and final responsibility for the
- decision to submit for publication.

354 Data availability Statement

- 355 Qualified investigators may gain access to the WHI data through the WHI data coordinating
- 356 center after securing approval of a paper proposal as described here
- 357 <u>https://www.whi.org/propose-a-paper</u>. Data is also accessible through BiolinC at
- 358 <u>https://biolincc.nhlbi.nih.gov/studies/whi_ctos/</u> and through dbGAP at
- 359 <u>https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v12.p3</u> The
- 360 1000G reference panel used for joint imputation can be accessed through
- 361 <u>https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000746.v1.p3</u>.

363 Conflict of Interest

364 Nothing to disclose.

Reference

- 1. Rosamond WD, Chambless LE, Heiss G, Mosley TH, Coresh J, Whitsel E, Wagenknecht L, Ni H, Folsom AR. Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008. *Circulation.* 2012;125:1848-1857. doi: 10.1161/CIRCULATIONAHA.111.047480
- Smith SC, Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. *Circulation*. 2011;124:2458-2473. doi: 10.1161/CIR.0b013e318235eb4d
- 3. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. *Circulation*. 2017;135:e146-e603. doi: 10.1161/CIR.00000000000485
- 4. Ridker PM, Libby P, Buring JE. Risk Markers and the Primary Prevention of Cardiovascular Disease. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, eds. *Braunwald's heart disease : a textbook of cardiovascular medicine*. Philadelphia, PA: Elsevier/Saunders; 2015:891-933.
- 5. Levitan EB, Tanner RM, Zhao H, Muntner P, Thacker EL, Howard G, Glasser SP, Bittner V, Farkouh ME, Rosenson RS, et al. Secular changes in rates of coronary heart disease, fatal coronary heart disease, and out-of-hospital fatal coronary heart disease. *Int J Cardiol.* 2014;174:436-439. doi: 10.1016/j.ijcard.2014.04.027
- Vasan RS, Enserro DM, Xanthakis V, Beiser AS, Seshadri S. Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study. *Circulation*. 2022;145:1324-1338. doi: 10.1161/CIRCULATIONAHA.121.057889
- Bogle BM, Ning H, Mehrotra S, Goldberger JJ, Lloyd-Jones DM. Lifetime Risk for Sudden Cardiac Death in the Community. *J Am Heart Assoc*. 2016;5. doi: 10.1161/JAHA.115.002398
- Pearte CA, Furberg CD, O'Meara ES, Psaty BM, Kuller L, Powe NR, Manolio T. Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: the Cardiovascular Health Study. *Circulation*. 2006;113:2177-2185. doi: 10.1161/CIRCULATIONAHA.105.610352
- 9. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL. Implementation of the Women's Health Initiative study design. *Ann Epidemiol*. 2003;13:S5-17.
- 10. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. *Controlled clinical trials*. 1998;19:61-109.
- Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw JE. The Women's Health Initiative recruitment methods and results. *Ann Epidemiol*. 2003;13:S18-77. doi: 10.1016/s1047-2797(03)00042-5

- 12. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. *Ann Epidemiol*. 2003;13:S122-128. doi: 10.1016/s1047-2797(03)00048-6
- Sims ST, Kubo J, Desai M, Bea J, Beasley JM, Manson JE, Allison M, Seguin RA, Chen Z, Michael YL, et al. Changes in physical activity and body composition in postmenopausal women over time. *Med Sci Sports Exerc*. 2013;45:1486-1492. doi: 10.1249/MSS.0b013e31828af8bd
- Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, Lai FY, Kaptoge S, Brozynska M, Wang T, et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention. *J Am Coll Cardiol*. 2018;72:1883-1893. doi: 10.1016/j.jacc.2018.07.079
- 15. Lunn M, McNeil D. Applying Cox regression to competing risks. *Biometrics*. 1995;51:524-532.
- Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. *Am J Epidemiol*. 2005;162:975-982. doi: 10.1093/aje/kwi309
- 17. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. *Stat Med.* 2007;26:2389-2430. doi: 10.1002/sim.2712
- 18. Chatterjee N, Sinha S, Diver WR, Feigelson HS. Analysis of cohort studies with multivariate and partially observed disease classification data. *Biometrika*. 2010;97:683-698. doi: 10.1093/biomet/asq036
- 19. Bartlett JW, Seaman SR, White IR, Carpenter JR. Multiple imputation of covariates by fully conditional specification: Accommodating the substantive model. *Stat Methods Med Res.* 2015;24:462-487. doi: 10.1177/0962280214521348
- 20. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. 2011;45:1 67. doi: 10.18637/jss.v045.i03
- 21. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate a Practical and Powerful Approach to Multiple Testing. *J R Stat Soc B*. 1995;57:289-300. doi: DOI 10.1111/j.2517-6161.1995.tb02031.x
- 22. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. *J Am Coll Cardiol*. 1995;25:417-423. doi: 10.1016/0735-1097(94)00371-v
- 23. Chatterjee NA. Prediction of Sudden Cardiac Death: Looking Beyond Ejection Fraction. *Curr Cardiol Rep.* 2023. doi: 10.1007/s11886-023-01871-0
- 24. Desai AD, Yaw TS, Yamazaki T, Kaykha A, Chun S, Froelicher VF. Prognostic Significance of Quantitative QRS Duration. *Am J Med.* 2006;119:600-606. doi: 10.1016/j.amjmed.2005.08.028
- 25. Davey P. QT interval and mortality from coronary artery disease. *Prog Cardiovasc Dis.* 2000;42:359-384. doi: 10.1053/pcad.2000.0420359
- 26. Kramer B, Brill M, Bruhn A, Kubler W. Relationship between the degree of coronary artery disease and of left ventricular function and the duration of the QT-interval in ECG. *European heart journal*. 1986;7:14-24. doi: 10.1093/oxfordjournals.eurheartj.a061951

- 27. Winell KM, Pääkkönen R, Pietilä A, Niemi MK, Reunanen AR, Salomaa VV. Case fatality rates after first acute coronary syndrome in persons treated for type 2 diabetes show an improving trend. *Diabetologia*. 2010;53:472-480. doi: 10.1007/s00125-009-1606-2
- Icks A, Claessen H, Kirchberger I, Heier M, Peters A, Trentinaglia I, Giani G, von Scheidt W, Meisinger C. Mortality after first myocardial infarction in diabetic and nondiabetic people between 1985 and 2009. The MONICA/KORA registry. *Eur J Epidemiol*. 2014;29:899-909. doi: 10.1007/s10654-014-9964-6
- 29. Nedkoff L, Knuiman M, Hung J, Briffa TG. Improving 30-day case fatality after incident myocardial infarction in people with diabetes between 1998 and 2010. *Heart*. 2015;101:1318-1324. doi: 10.1136/heartjnl-2015-307627
- Karmali KN, Lloyd-Jones DM, Berendsen MA, Goff DC, Jr., Sanghavi DM, Brown NC, Korenovska L, Huffman MD. Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. *JAMA Cardiol*. 2016;1:341-349. doi: 10.1001/jamacardio.2016.0218
- Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. *J Clin Epidemiol*. 2010;63:64-74. doi: 10.1016/j.jclinepi.2009.03.001
- Gärtner C, Walz L, Bauernschmitt E, Ladwig KH. The causes of prehospital delay in myocardial infarction. *Dtsch Arztebl Int*. 2008;105:286-291. doi: 10.3238/arztebl.2008.0286
- Shiroma EJ, Lee IM. Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. *Circulation*. 2010;122:743-752. doi: 10.1161/CIRCULATIONAHA.109.914721
- 34. Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. *Prog Cardiovasc Dis.* 2003;46:31-38. doi: 10.1016/s0033-0620(03)00078-1
- 35. Davidson KW, Barry MJ, Mangione CM, Cabana M, Chelmow D, Coker TR, Davis EM, Donahue KE, Jaén CR, Krist AH, et al. Aspirin Use to Prevent Cardiovascular Disease. *JAMA*. 2022;327:1577. doi: 10.1001/jama.2022.4983
- 36. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O'Brien WL, Bassett DR, Jr., Schmitz KH, Emplaincourt PO, et al. Compendium of physical activities: an update of activity codes and MET intensities. *Med Sci Sports Exerc*. 2000;32:S498-504.
- 37. Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, Perri MG, Sheps DS, Pettinger MB, Siscovick DS. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. *N Engl J Med.* 2002;347:716-725. doi: 10.1056/NEJMoa021067
- 38. Sims ST, Kubo J, Desai M, Bea J, Beasley JM, Manson JE, Allison M, Seguin RA, Chen Z, Michael YL, et al. Changes in physical activity and body composition in postmenopausal women over time. *Med Sci Sports Exerc*. 2013;45:1486-1492. doi: 10.1249/MSS.0b013e31828af8bd

- 39. Chiuve SE, Fung TT, Rimm EB, Hu FB, McCullough ML, Wang M, Stampfer MJ, Willett WC. Alternative dietary indices both strongly predict risk of chronic disease. J Nutr. 2012;142:1009-1018. doi: 10.3945/jn.111.157222
- 40. Rautaharju PM, Park LP, Chaitman BR, Rautaharju F, Zhang ZM. The Novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. *J Electrocardiol*. 1998;31:157-187.
- 41. Prineas RJ, Crow RS, Zhang Z-M. *The Minnesota code manual of electrocardiographic findings, including measurement and comparison with the Novacode : standards and procedures for ECG measurement in epidemiologic and clinical trials.* 2nd ed. London: Springer; 2010.
- 42. Xue X, Kim MY, Gaudet MM, Park Y, Heo M, Hollenbeck AR, Strickler HD, Gunter MJ. A comparison of the polytomous logistic regression and joint cox proportional hazards models for evaluating multiple disease subtypes in prospective cohort studies. *Cancer Epidemiol Biomarkers Prev.* 2013;22:275-285. doi: 10.1158/1055-9965.EPI-12-1050
- 43. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiology*. 2000;11:550-560. doi: 10.1097/00001648-200009000-00011

Table 1. Baseline characteristics of study participants

		Non-event		on-fatal CHD	Definitive fatal CHD		
	(N = 137516)			(N = 10201)	(N = 513)		
Characteristics	Ν	Mean (SD) or median	Ν	Mean (SD) or median	Ν	Mean (SD) or median	
		[IQR] or %		[IQR] or %		[IQR] or %	
Demographics/anthropometric							
Age (years)	137516	62.7 (7.2)	10201	65.6 (6.7)	513	68.6 (6.5)	
Race (%)							
European American	113878	83.0	8703	85.5	440	85.9	
African American	11833	8.6	879	8.6	50	9.8	
Hispanics	5547	4.0	308	3.0	10	2.0	
Asians or Pacific Islander	3794	2.8	142	1.4	6	1.2	
BMI (kg/m^2)	136322	27.8 (5.9)	10123	29.0 (6.0)	508	29.1 (6.5)	
SBP (mmHg)	137408	128.5 (19.1)	10194	137.3 (19.8)	512	140.2 (20.7)	
Medical history (%)							
Treated hypertension	137516	21.6	10201	35.7	513	40.9	
Treated diabetes	137516	3.1	10201	10.1	513	11.5	
Lifestyles and social economic factors							
Current smoker (%)	137427	6.5	10195	8.6	512	10.2	
Physical activity (MET hr/week)	137427	8.0 [1.5, 17.5]	10195	6.2 [0.8, 15.2]	512	5.8 [0.5, 14.7]	
AHEI score	134880	59.0 (11.5)	10000	57.7 (11.3)	503	58.8 (10.8)	
Education level	136491	7.3 (1.9)	10120	6.9 (1.9)	508	7.1 (1.9)	
Family income	131994	4.3 (1.8)	9818	3.8 (1.7)	492	3.7 (1.8)	
Medication use (%)		× /					
Aspirin	137514	18.6	10201	25.0	513	20.9	
Statin	137514	6.1	10201	10.3	513	9.2	
Beta-blocker	137514	6.9	10201	11.6	513	10.7	
CCB	137514	7.8	10201	16.1	513	17.9	
RAS inhibitor	137514	7.6	10201	12.4	513	14.6	
Diuretics	137514	10.6	10201	16.2	513	18.7	
ECG measures							
Bradycardia (%)	53499	2.6	4615	2.9	216	2.3	
LVHI	53132	80.0 [76.0, 84.0]	4584	82.0 [78.0, 87.0]	212	82.0 [78.0, 88.0]	
LVHI_CAT (%)	53132	0.2	4584	0.7	212	3.3	
NOVA5 (%)	51735	28.6	4383	40.2	197	44.7	
MC_MI (%)	51667	2.0	4378	3.7	197	5.6	
Biomarkers	· ·						
HDLC (mg/dL)	29169	55.5 (14.4)	4624	51.1 (13.8)	293	51.5 (14.6)	
LDLC (mg/dL)	24127	143.8 (37.4)	3838	148.6 (37.9)	239	146.6 (38.6)	

TG (mg/dL)	27547	120.0 [87.0, 168.0]	4284	143.7 [105.0, 197.0]	259	132.0 [96.0, 198.0]
FG (mg/dL)	30281	94.0 [87.0, 103.0]	3577	97.0 [89.0, 113.0]	227	98.0 [90.0, 110.0]
FI (uU/mL)	28751	8.0 [5.2, 12.5]	3196	9.7 [6.2, 15.1]	180	9.3 [6.1, 14.5]
Creatinine (mg/dL)	20531	0.7 [0.7, 0.8]	2307	0.7 [0.7, 0.8]	124	0.8 [0.7, 0.9]
C-reactive protein (mg/dL)	36210	2.6 [1.1, 5.5]	4383	3.3 [1.5, 6.6]	293	3.5 [1.7, 7.6]
Meta-GRS (SD)	20374	-0.1 (1.0)	2314	0.2 (0.9)	129	0.2 (0.9)

N: total number of participants with non-missing covariate value. BMI: body mass index; SBP: systolic blood pressure; MET min/week: metabolic equivalent minutes per week of recreational activity; AHEI score: Alternative Healthy Eating Index score; CCB: calcium-channel blocker; RAS inhibitors: renin-angiotensin system inhibitors; LVHI: left ventricular hypertrophy index; LVHI_CAT: Left Ventricular Hypertrophy Index > 120 (1 vs 0); NOVA5: Novacode 5 for Myocardial Infarction / Ischemia; MC_MI: MI by Minnesota Code; HDLC: high-density lipoprotein cholesterol; LDLC: low-density lipoprotein cholesterol; TG: triglycerides; FG: fasting glucose; FI: fasting insulin; Education level was modeled as a continuous variable ranging from 1 to 11; Family income was modeled as a continuous variable ranging from 1 to 11; Family income was modeled as a continuous variable ranging from 1 to 11; Family income was modeled as a continuous variable ranging from 1 to 11; Family income was modeled as a continuous variable ranging from 1 to 11; Family income was modeled as a continuous variable ranging from 1 to 9; Meta-GRS: standard deviation of the normalized weighted genetic risk score of 1.7 million polymorphic susceptibility variants for CHD. Descriptive statistics for continuous variables that follow normal distribution, continuous variables that do not follow normal distribution, and binary variables were expressed as mean (standard deviation), median (fist quartile, third quartile), and percentage respectively.

Non-fatal CHD (N = 10201)				Definitive fatal CHD (N = 513)			Definitive fatal CHD			
D'il Conton	$\frac{\text{vs. non-event (N = 137516)}}{\text{LID}_{(0.50)}(\text{CI)}}$			vs. non-event			vs. non-fatal CHD			
Risk factor	HR (95%CI)	Р	FDR-q	HR (95%CI)	Р	FDR-q	HR (95%CI)	Р	FDR-q	
Age	1.27 (1.25, 1.28)	2.3E-199	6.2E-198	1.85 (1.71, 2)	3.1E-52	8.4E-51	1.46 (1.35, 1.58)	3.7E-20	1.0E-18	
BMI	1.04 (1.02, 1.06)	4.9E-06	7.8E-06	1.04 (0.96, 1.13)	0.31	0.45	1 (0.92, 1.09)	0.93	0.97	
SBP	1.1 (1.09, 1.11)	7.3E-58	6.6E-57	1.08 (1.02, 1.14)	3.9E-03	1.8E-02	0.98 (0.93, 1.03)	0.48	0.74	
Treated Diabetes	2.01 (1.91, 2.13)	4.5E-134	6.1E-133	1.85 (1.46, 2.35)	4.4E-07	4.0E-06	0.92 (0.72, 1.17)	0.49	0.74	
Treated Hypertension	1.48 (1.4, 1.56)	2.6E-43	1.8E-42	1.78 (1.41, 2.25)	1.3E-06	8.8E-06	1.21 (0.95, 1.53)	0.13	0.39	
Smoking	1.09 (1.07, 1.12)	1.7E-21	7.6E-21	1.24 (1.15, 1.35)	1.3E-07	1.8E-06	1.14 (1.04, 1.23)	2.7E-03	2.4E-02	
PA	0.93 (0.91, 0.94)	2.5E-14	5.6E-14	0.81 (0.74, 0.89)	5.5E-06	3.0E-05	0.88 (0.8, 0.96)	5.2E-03	3.5E-02	
AHEI score	0.89 (0.85, 0.94)	1.5E-06	2.5E-06	1.03 (0.84, 1.25)	0.79	0.89	1.15 (0.94, 1.4)	0.18	0.49	
Education	0.95 (0.94, 0.96)	7.3E-18	2.5E-17	1.01 (0.96, 1.07)	0.64	0.77	1.06 (1.01, 1.12)	2.0E-02	0.11	
Income	0.95 (0.93, 0.96)	4.4E-17	1.3E-16	0.95 (0.89, 1)	0.07	0.19	1 (0.94, 1.06)	0.97	0.97	
Aspirin	1.19 (1.14, 1.24)	3.5E-15	8.6E-15	0.82 (0.67, 1)	0.05	0.17	0.69 (0.56, 0.84)	2.9E-04	3.9E-03	
Statin	1.2 (1.14, 1.26)	4.3E-12	8.9E-12	0.95 (0.76, 1.2)	0.66	0.77	0.79 (0.63, 1)	0.05	0.17	
Betablocker	1.27 (1.21, 1.34)	8.6E-19	3.3E-18	1.15 (0.91, 1.45)	0.23	0.41	0.9 (0.71, 1.14)	0.4	0.74	
CCB	1.32 (1.25, 1.4)	1.1E-24	5.9E-24	1.28 (1.02, 1.61)	3.2E-02	0.12	0.97 (0.77, 1.22)	0.78	0.93	
RASI	1.03 (0.98, 1.09)	0.21	0.22	1.12 (0.9, 1.39)	0.32	0.45	1.08 (0.86, 1.35)	0.5	0.74	
Diuretics	0.97 (0.92, 1.02)	0.17	0.19	1.01 (0.81, 1.25)	0.94	0.97	1.04 (0.83, 1.31)	0.7	0.9	

 Table 2. Association between premorbid predictors and each of the two types of incident CHD events derived from a joint multivariate

 Cox model, followed by the relative hazard ratio for a fatal vs. a non-fatal CHD event, of all participants after imputing missingness.

Significant original p values (P) and FDR-q values under alpha level of 0.05 were written in scientific notation. Other covariates adjusted in the model but not shown in this table included: ethnicity, clinical trial vs observational study arms, hormone use ever. Age, per 5 years of increase; BMI, body mass index, per 5 units of increase; SBP, systolic blood pressure, per 10 mmHg of increase; AHEI score, Alternative Healthy Eating Index score, per 25 points of increase; CCB, calcium-channel blocker; RASI, renin-angiotensin system inhibitors. Smoking is modeled as an ordinal variable ranging from 0 to 4, representing <1, 1-4, 5-34, 35-44, ≥45 cigarettes/day respectively. PA, physical activity, modeled as an ordinal variable ranging from 0 to 3, representing 0-100, 100-500, 500-1200, >1200 metabolic equivalent minutes per week of recreational activity. Age, AHEI score, education, and family income were measured at baseline and modeled as time-fixed variables. BMI, SBP, diabetes, hypertension, smoking, physical activity, medications were repeatedly measured and modeled as time-dependent variable.






Figure 1. Flow diagram of Women's Health Initiative participants and outcomes examined in this study during the period 1993-2015. ASCVD: atherosclerosis related cardiovascular disease, CHF: congestive heart failure, CHD: coronary heart disease; CHD cases include individuals whose initial presentation of CHD during follow up was adjudicated as myocardial infarction (MI), a coronary revascularization procedure (CREVASC), a definite death from CHD. CHD cases are considered fatal if the participant died within 28 days of her first CHD event.








Figure 3. Estimated cumulative absolute risk of a fatal presentation of CAD over a 20 year follow up for subgroup of women using a joint multivariate Cox model. The cumulative probability of a fatal incident CHD event was modeled taking into consideration the competing risk of a non-fatal CHD event. Left graph compares the hazard function of women aged 55, 65, and 75 at baseline with and without healthy lifestyles as defined by no smoking and > 1200 MET min/week of PA vs. smoking 35 to 44 cigarettes/day and < 100 MET min/week of PA. Right graph compares women aged 75 at baseline with and without use of aspirin in addition to women with and without a healthy lifestyle.

В.

Α.